Entering text into the input field will update the search result below

As amyloid-targeting therapies for Alzheimer's fail, where might success lie?

Alzheimers

tupungato/iStock via Getty Images

Mid- and late-stage data readouts over the last few years for Alzheimer's therapies have had a similar theme: Failure.

Almost all these candidates have one thing in common: They target reducing beta-amyloid plaque in the brain

Recommended For You

Related Stocks

SymbolLast Price% Chg
LLY--
Eli Lilly and Company
BIIB--
Biogen Inc.
RHHBY--
Roche Holding AG
SAVA--
Cassava Sciences, Inc.